Trained immunity is an emerging field that describes the innate immune system’s ability to develop memory-like characteristics following exposure to ...

ImmunityBio's stock has roughly quintupled so far in 2026 as the company continues to deliver good news for investors.

A vaccine usually trains your immune system to recognize one target. Here, the target is basically “anything that doesn’t belong in the lungs.

Stanford Medicine researchers have developed an intranasal liposomal vaccine that protected mice against SARS-CoV-2, ...

In an early animal test, a new nasal-spray vaccine has shown promise against a variety of germs and a common allergen, ...

In what could be considered a revolutionary breakthrough, scientists have created a “universal” vaccine formula that protects mice against a suite of respiratory viruses, bacteria, and even allergens.

Researchers suggest a vaccine could replace multiple jabs every year for seasonal respiratory infections and be on hand in the event of a new pandemic.

An innovative approach supercharges the innate immune system to provide a first line of defence against respiratory ...

ImmunityBio partner Accord Healthcare to deploy an 85-person sales force to drive ANKTIVA commercialization across 30 countries -- Dublin-based subsidiary to support ImmunityBio's distribution and ...

On Feb. 18, 2026, investors weighed ImmunityBio’s EU bladder cancer win against its long slide since IPO and fresh legal ...

ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe ...

Ana Santos Rutschman does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations ...